ERBB2 and non-small cell lung carcinoma: An updated analysis of zongertinib in patients with HER2-mutant NSCLC demonstrated an ORR of 72% and a disease control rate (DCR) of 95.5%, with manageable adverse effects, including low rates of severe diarrhea and liver enzyme elevations.